2566 — Hangzhou Jiuyuan Genetic Biopharmaceutical Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapContrarian

Market Cap
HK$2.25bn
Enterprise Value
HK$1.61bn
Revenue
CNY1.31bn

Annual cashflow statement for Hangzhou Jiuyuan Genetic Biopharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	128	51.4	135	169	162
Depreciation
Amortisation
Non-Cash Items	10.9	11.2	23.6	26.2	4.01
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-95.2	-75.8	-58.9	-137	44.7
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	67.5	22.6	136	94.8	255
Capital Expenditures	-62.9	-59	-47	-79.8	-105
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	0.048	0.011	0.002	0.119	-300
Sale of Fixed Assets
Other Investing Cash Flow
Cash from Investing Activities	-62.9	-58.9	-47	-79.7	-405
Financing Cash Flow Items	-9.74	-21	-14.5	-46.3	-4.54
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	41.2	12.9	-67.3	428	-39.4
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	45.8	-23.3	21.6	444	-189